- Conditions
- Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
- Interventions
- Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]
- Procedure · Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 54
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Melanoma
- Interventions
- Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
- Biological · Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Interventions
- bortezomib, plasmapheresis
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
- Conditions
- Apheresis Related Hypotension
- Interventions
- Updated Plasma Collection Feature, Current Plasma Collection Approach
- Device
- Lead sponsor
- Haemonetics Corporation
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 3,443 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 3
- States / cities
- Wichita, Kansas • Charlotte, North Carolina • Spokane, Washington
- Conditions
- Plasma Exchange
- Interventions
- 20-gauge BD Nexiva Diffusics
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Aging
- Interventions
- Sham, Therapeutic Plasma Exchange, IVIG
- Device · Drug
- Lead sponsor
- Dobri Kiprov
- Industry
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Mill Valley, California
- Conditions
- Therapeutic Plasma Exchange, Anticoagulant Therapy
- Interventions
- Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
- Device · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 0 Years to 24 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Interventions
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 33
- States / cities
- Scottsdale, Arizona • Loma Linda, California • Sacramento, California + 25 more
- Conditions
- Adverse Effects in the Therapeutic Use of Plasma Substitutes
- Interventions
- Octaplas™
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • New Orleans, Louisiana + 5 more
- Conditions
- Apheresis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 864 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1988 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Rituximab, Plasma exchange, Corticosteroids
- Drug · Procedure
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Danazol
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19
- Interventions
- Convalescent Plasma
- Biological
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Ebola Virus Disease, Marburg Virus Disease
- Interventions
- cAd3-Marburg, cAd3-EBO-S
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Age-Related Frailty
- Interventions
- Therapeutic Plasma Exchange (TPE)
- Other
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Anthrax
- Interventions
- Anthrax Immune Globulin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mild Cognitive Impairment
- Interventions
- Plasmapheresis, Plasma infusion
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- Albumin 5%, Albumin 20%, Immunoglobulin
- Biological
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 22
- States / cities
- Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Plasma exchange, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Transplantation, Plasmapheresis
- Interventions
- tacrolimus, mycophenolate mofetil, daclizumab, intravenous immune globulin, plasmapheresis
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, Plasmapheresis
- Genetic · Procedure
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 8 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • St Louis, Missouri • Columbus, Ohio
- Conditions
- Leukopheresis, Plasmapheresis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Albutein 5%, Plasma Exchange
- Biological · Procedure
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 19 Years to 69 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more